Brief Summary
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab in subjects with locally advancedat a late stage, far along and unresectable or metastatic non-small cell lung cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs with a KRAS (Kirsten rat sarcomacancer arising from bones and/or soft tissue) G12C mutation.
Intervention / Treatment
- Drug: BBO-8520
- Drug: Pembrolizumab
Inclusion Criteria:
- Histologically documented locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS G12C mutation
- Measurable disease by RECIST v1.1
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status (PS) 0-1